To aid in your quest to continue believing...

“Dealing with the development and regulatory process for a drug has proven more

difficult than for devices,” Mann shares. “The enormous cost and time result from

the zero tolerance for risk in our country,” he adds. There are about 23.6 million

people in the U.S. who have diabetes and another 40 million or more who have

the beginnings of the disease and could benefit from this product. And there are

millions more worldwide who suffer from diabetes. Mann predicts the company’s

stock, MNKD on NASDAQ, will eventually soar."

Alfred E. Mann - A Mann of His Word

http://davidovit.com/articles/Al-Mann-Article.pdf

"But he is a visionary. “I think that what people say most about me is that I can
see the end when I start,” he shares. Though he is cognizant of hurdles, he is never
deterred by them or afraid of them. “Fear has never helped anyone do anything.”